RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Assessing Patient Understanding of Medication Guides

Assessing Patient Understanding of Medication Guides

Posted 01 October 2010 | By

The passage of the Food And Drug Administration Amendments Act of 2007 (FDAAA) modified the Food, Drug, and Cosmetic Act and, specifically, created Section 505-1 to give FDA the authority to require Risk Evaluation and Mitigation Strategies (REMS) for certain drugs and biologics. The purpose of a REMS is to ensure that a drug's benefits outweigh its risks. A common element of all REMS is periodic assessment of the effectiveness of the strategy. FDAAA specifies assessments at 18 months and three years after approval of the REMS, and also in the seventh year.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.